United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,235 shares of the stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $131.95, for a total transaction of $162,958.25. Following the transaction, the chief executive officer now owns 2,304 shares of the company’s stock, valued at approximately $304,012.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of United Therapeutics Corporation (UTHR) traded down 0.74% during mid-day trading on Thursday, reaching $131.06. 618,908 shares of the company’s stock were exchanged. The company has a market cap of $5.69 billion, a PE ratio of 15.20 and a beta of 1.51. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89. The company’s 50-day moving average price is $130.48 and its 200 day moving average price is $134.58.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.61 by $4.86. The firm had revenue of $444.60 million for the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. United Therapeutics Corporation’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.42 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post $10.09 EPS for the current year.

United Therapeutics Corporation declared that its board has initiated a share buyback program on Thursday, April 27th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the biotechnology company to repurchase up to 4.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/17/insider-selling-united-therapeutics-corporation-uthr-ceo-sells-1235-shares-of-stock.html.

Several research analysts recently commented on UTHR shares. Zacks Investment Research cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. BidaskClub cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Monday, July 31st. ValuEngine upgraded shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. Wedbush restated an “outperform” rating and set a $213.00 target price (down previously from $229.00) on shares of United Therapeutics Corporation in a report on Thursday, April 27th. Finally, UBS AG restated a “sell” rating and set a $106.00 target price on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Six research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $134.50.

A number of institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in shares of United Therapeutics Corporation by 1.8% in the first quarter. JPMorgan Chase & Co. now owns 122,497 shares of the biotechnology company’s stock worth $16,583,000 after buying an additional 2,223 shares during the period. Clarity Capital KCPS Ltd. bought a new position in shares of United Therapeutics Corporation during the first quarter worth $230,000. Argent Capital Management LLC increased its position in shares of United Therapeutics Corporation by 2.4% in the first quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock worth $343,000 after buying an additional 60 shares during the period. Greylin Investment Mangement Inc. increased its position in shares of United Therapeutics Corporation by 42.3% in the second quarter. Greylin Investment Mangement Inc. now owns 2,975 shares of the biotechnology company’s stock worth $386,000 after buying an additional 885 shares during the period. Finally, Nuveen Asset Management LLC increased its position in shares of United Therapeutics Corporation by 222.1% in the first quarter. Nuveen Asset Management LLC now owns 64,507 shares of the biotechnology company’s stock worth $8,733,000 after buying an additional 44,481 shares during the period.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.